175 related articles for article (PubMed ID: 11150537)
1. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.
van der Vliet HJ ; Nishi N; Koezuka Y; von Blomberg BM ; van den Eertwegh AJ ; Porcelli SA; Pinedo HM; Scheper RJ; Giaccone G
J Immunol Methods; 2001 Jan; 247(1-2):61-72. PubMed ID: 11150537
[TBL] [Abstract][Full Text] [Related]
2. Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells.
Van Der Vliet HJ; Nishi N; Koezuka Y; Peyrat MA; Von Blomberg BM; Van Den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
Immunology; 1999 Dec; 98(4):557-63. PubMed ID: 10594688
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro.
Nishi N; van der Vliet HJ; Koezuka Y; von Blomberg BM; Scheper RJ; Pinedo HM; Giaccone G
Hum Immunol; 2000 Apr; 61(4):357-65. PubMed ID: 10715513
[TBL] [Abstract][Full Text] [Related]
4. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
[TBL] [Abstract][Full Text] [Related]
5. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
[TBL] [Abstract][Full Text] [Related]
6. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients.
van der Vliet HJ; Molling JW; von Blomberg BM; Kölgen W; Stam AG; de Gruijl TD; Mulder CJ; Janssen HL; Nishi N; van den Eertwegh AJ; Scheper RJ; van Nieuwkerk CJ
Clin Immunol; 2005 Feb; 114(2):183-9. PubMed ID: 15639652
[TBL] [Abstract][Full Text] [Related]
7. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes.
Gadola SD; Dulphy N; Salio M; Cerundolo V
J Immunol; 2002 Jun; 168(11):5514-20. PubMed ID: 12023346
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.
Nieda M; Okai M; Tazbirkova A; Lin H; Yamaura A; Ide K; Abraham R; Juji T; Macfarlane DJ; Nicol AJ
Blood; 2004 Jan; 103(2):383-9. PubMed ID: 14512316
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
[TBL] [Abstract][Full Text] [Related]
10. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
[TBL] [Abstract][Full Text] [Related]
11. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
[TBL] [Abstract][Full Text] [Related]
12. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.
Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T
J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949
[TBL] [Abstract][Full Text] [Related]
13. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells.
Takahashi T; Chiba S; Nieda M; Azuma T; Ishihara S; Shibata Y; Juji T; Hirai H
J Immunol; 2002 Apr; 168(7):3140-4. PubMed ID: 11907064
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
[TBL] [Abstract][Full Text] [Related]
15. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
16. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
[TBL] [Abstract][Full Text] [Related]
17. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.
Benlagha K; Weiss A; Beavis A; Teyton L; Bendelac A
J Exp Med; 2000 Jun; 191(11):1895-903. PubMed ID: 10839805
[TBL] [Abstract][Full Text] [Related]
18. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.
Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ
PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686
[TBL] [Abstract][Full Text] [Related]
19. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand.
Kawano T; Tanaka Y; Shimizu E; Kaneko Y; Kamata N; Sato H; Osada H; Sekiya S; Nakayama T; Taniguchi M
Int Immunol; 1999 Jun; 11(6):881-7. PubMed ID: 10360961
[TBL] [Abstract][Full Text] [Related]
20. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
